SELLAS Life Sciences Group, Inc.

Two experimental cancer drugs carry SELLAS Life Sciences, a clinical-stage biopharmaceutical company with no marketed products and no revenue yet. Its lead candidate, galinpepimut-S, is an immunotherapy aimed at WT1, a protein found in a range of tumors that the National Cancer Institute has flagged as a high-priority target; it has been tested in acute myeloid leukemia and other cancers. The second, SLS009, is a small molecule designed to block CDK9, an enzyme cancer cells rely on. Based in New York, the company lives on the outcome of its clinical trials: positive late-stage data could be transformative, while a failure would be severe, which is the standard risk profile for a development-stage drug developer. It funds itself by raising capital rather than from sales, so cash runway and trial timelines matter as much as the underlying science.

On MyRWA, SLS trades tokenized across 2 on-chain venues - see the listings below.